Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 242

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 242
---
 experience and business developments. Furthermore, the financial projections do not take into account
any circumstances or events occurring after the date they were prepared.

| 120 |

EXCEPT TO THE EXTENT REQUIRED BY
APPLICABLE FEDERAL SECURITIES LAWS, BY INCLUDING IN THIS PROXY STATEMENT/PROSPECTUS A SUMMARY OF THE FINANCIAL PROJECTIONS FOR LONGEVITY
ANDFUTURETECH UNDERTAKE NO OBLIGATIONS AND EXPRESSLY DISCLAIM ANY RESPONSIBILITY TO UPDATE OR REVISE, OR PUBLICLY DISCLOSE ANY UPDATE
OR REVISION TO, THESE FINANCIAL PROJECTIONS TO REFLECT CIRCUMSTANCES OR EVENTS, INCLUDING UNANTICIPATED EVENTS, THAT MAY HAVE OCCURRED
OR THAT MAY OCCUR AFTER THE PREPARATION OF THESE FINANCIAL PROJECTIONS, EVEN IN THE EVENT THAT ANY OR ALL OF THE ASSUMPTIONS UNDERLYING
THE FINANCIAL PROJECTIONS ARE SHOWN TO BE IN ERROR OR CHANGE. NONE OF LONGEVITY, FUTURETECH NOR ANY OF THEIR RESPECTIVE AFFILIATES, OFFICERS,
DIRECTORS, ADVISORS OR OTHER REPRESENTATIVES HAS MADE OR MAKES ANY REPRESENTATION TO ANY EQUITYHOLDER OF LONGEVITY, FUTURETECH OR FUTURETECH
OR ANY OTHER PERSON REGARDING ULTIMATE PERFORMANCE COMPARED TO THE INFORMATION CONTAINED IN THE FINANCIAL PROJECTIONS OR THAT FINANCIAL
AND OPERATING RESULTS WILL BE ACHIEVED.

The financial
projections included in this document have been prepared by, and are the responsibility of, Longevity’s management. Marcum LLP,
in its capacity as Longevity’s independent registered public accounting firm, has not audited, reviewed, examined, compiled or applied
agreed-upon procedures with respect to the accompanying financial projections and, accordingly, Marcum LLP expresses no opinion or any
other form of assurance with respect thereto.

The Projections

The key elements
of the Projections provided by Longevity’s management team to FutureTech are summarized in the tables below. The financial projections
assume the consummation of the Business Combination and the Target Acquisitions and reflect numerous assumptions which are difficult to
predict and many of which are beyond Longevity’s control. The development and regulatory timelines for biomedical products are generally
long and can frequently take a decade or more before a product is approved. As discussed above, the projections presented below are for
an eight-year period